Octave Bioscience Awarded Valhalla Foundation Grant to Accelerate Development of the First MS Disease Progression Test

MENLO PARK, Calif.–(BUSINESS WIRE)–Octave Bioscience, Inc., a commercial-stage precision care company pioneering biomarker-driven solutions for multiple sclerosis (MS) and other neurodegenerative diseases, today announced that it is…

Continue Reading